Summary
Global Markets Direct’s, ‘AstraZeneca Plc - Product Pipeline Review - 2016’, provides an overview of the AstraZeneca Plc’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by AstraZeneca Plc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of AstraZeneca Plc
- The report provides overview of AstraZeneca Plc including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses AstraZeneca Plc’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features AstraZeneca Plc’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate AstraZeneca Plc’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for AstraZeneca Plc
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding AstraZeneca Plc’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 7
AstraZeneca Plc Snapshot 8
AstraZeneca Plc Overview 8
Key Information 8
Key Facts 8
AstraZeneca Plc - Research and Development Overview 9
Key Therapeutic Areas 9
AstraZeneca Plc - Pipeline Review 19
Pipeline Products by Stage of Development 19
Pipeline Products - Monotherapy 20
Pipeline Products - Combination Treatment Modalities 21
Pipeline Products - Partnered Products 22
Pipeline Products - Out-Licensed Products 25
AstraZeneca Plc - Pipeline Products Glance 27
AstraZeneca Plc - Late Stage Pipeline Products 27
AstraZeneca Plc - Clinical Stage Pipeline Products 30
AstraZeneca Plc - Early Stage Pipeline Products 34
AstraZeneca Plc - Drug Profiles 39
(avibactam + ceftazidime) 39
(dapagliflozin propanediol + saxagliptin) 41
(formoterol fumarate + glycopyrrolate) 43
(metformin hydrochloride + saxagliptin) 45
brodalumab 47
cangrelor tetrasodium 49
cediranib maleate 51
ceftaroline fosamil 54
dapagliflozin propanediol 57
osimertinib mesylate 60
propofol 63
ticagrelor 64
(aclidinium bromide + formoterol fumarate) 68
(budesonide + formoterol fumarate + glycopyrrolate) 70
(dapagliflozin propanediol + metformin hydrochloride + saxagliptin) 72
fulvestrant 74
gefitinib 76
glycopyrrolate 81
olaparib 83
omega-3-carboxylic acids 87
PT-009 89
quetiapine fumarate ER 90
roxadustat 91
selumetinib sulfate 94
AZD-3293 98
AZD-4547 99
(avibactam sodium + ceftaroline fosamil) 101
abediterol napadisylate 102
AZD-1775 104
AZD-1981 106
AZD-2014 107
AZD-3241 109
AZD-3759 110
AZD-4017 111
AZD-5363 113
AZD-7594 115
AZD-7624 116
AZD-9150 117
interferon beta-1a 118
lesogaberan 120
PT-008 121
RDEA-3170 122
sapitinib 123
saracatinib difumarate 125
savolitinib 127
Small Molecule for Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease 130
AZD-5069 131
AZD-5312 133
(allopurinol + lesinurad) 134
(avibactam sodium + aztreonam lysine) 135
(insulin human + pramlintide acetate) 136
ARC-165395XX 137
AZD-0156 138
AZD-0424 139
AZD-3965 140
AZD-4076 142
AZD-5634 143
AZD-5718 144
AZD-6738 145
AZD-7451 147
AZD-7986 148
AZD-8108 149
AZD-8186 150
AZD-8835 151
AZD-8871 152
AZD-8999 153
AZD-9496 154
AZD-9567 155
dabrafenib mesylate + durvalumab + trametinib dimethyl sulfoxide 156
LAS-40468 157
MEDI-7352 158
AC-163794 159
ADP-31417 160
ADP-71296 161
AZ-12260493 162
AZ-12441970 163
AZ-12861903 164
AZ-13483342 165
AZ-20 166
AZ-4217 167
AZ-4425 168
AZ-64 169
AZ-709 170
AZ-876 171
AZD-0449 172
AZD-2098 173
AZD-2858 174
AZD-3463 175
AZD-3857 176
AZD-4831 177
AZD-9708 178
CWGNC-41 179
Drug 1 for Cancer 180
Drug 2 for Cancer 181
Drug 3 for Cancer 182
Drug 4 for Cancer 183
Drug 5 for Cancer 184
Drug 6 for Cancer 185
HTL-1071 186
KU-59403 187
LAS-191351 188
LAS-194871 189
LCB-010200 190
MMV-253 191
Monoclonal Antibody Conjugates for Oncology 192
NBTI-5463 193
NKTR-119 194
OX-CLI 195
PL-8905 196
Small Molecule for Malaria 197
Small Molecule for Oncology 198
Small Molecule to Antagonize Histamine 3 Receptor for Cognition 199
Small Molecule to Antagonize Sphingosine 1 Phosphate Receptor 1 for Oncology 200
Small Molecule to Block Kv1.5 for Atrial Fibrillation 201
Small Molecule to Inhibit DNA Gyrase for Streptococcal Pneumonia 202
Small Molecule to Inhibit PI3K Beta for Bleeding and Clotting Disorders 203
Small Molecule to Inhibit Xanthine Oxidase for Hyperuricemia 204
Small Molecules 1 for Malaria 205
Small Molecules for Dyslipidemia and Hypertriglyceridemia 206
Small Molecules to Antagonize GPR103 for Obesity 207
Small Molecules to Antagonize M3 Receptors for Respiratory Disorders 208
Small Molecules to Antagonize P2X3 for Chronic Pain 209
Small Molecules to Inhibit CDK9 for Inflammatory Pain and Rheumatoid Arthritis 210
Small Molecules to Inhibit DNA GyrB for Tuberculosis 211
Small Molecules to Inhibit DprE1 for Tuberculosis 212
Synthetic Peptide for Neuropathic Pain 213
VU-0467154 214
AZ-0108 215
AZ-12201182 216
AZ-27 217
AZ-465 218
AZ-6142 219
AZ-82 220
AZD-3147 221
Drugs for Cardiovascular Diseases 222
HD-001 223
Small Molecule 1 for Malaria 224
Small Molecule to Inhibit 11beta-HSD-1 for Type 2 Diabetes 225
Small Molecule to Inhibit Src Tyrosine Kinase for Lymphangioleiomyomatosis 226
Small Molecules for Diabetic Nephropathy 227
Small Molecules for Tuberculosis 228
Small Molecules to Inhibit Acetohydroxyacid Synthase for Mycobacterium Infections 229
Small Molecules to Inhibit ATP Synthesis for Tuberculosis 230
Small Molecules to Inhibit Carboxypeptidase U for Thrombosis 231
Small Molecules to Inhibit DNA Gyrase B for Tuberculosis 232
Small Molecules to Inhibit DXP-Reductoisomerase for Malaria 233
Small Molecules to Inhibit MALT-1 for Oncology and Autoimmune Disorders 234
Small Molecules to Inhibit p38alpha MAP Kinase for Inflammatory Diseases 235
Small Molecules to Inhibit PLA2 for Undisclosed Indication 236
AstraZeneca Plc - Pipeline Analysis 237
AstraZeneca Plc - Pipeline Products by Target 237
AstraZeneca Plc - Pipeline Products by Route of Administration 246
AstraZeneca Plc - Pipeline Products by Molecule Type 247
AstraZeneca Plc - Pipeline Products by Mechanism of Action 248
AstraZeneca Plc - Recent Pipeline Updates 254
AstraZeneca Plc - Dormant Projects 316
AstraZeneca Plc - Discontinued Pipeline Products 319
Discontinued Pipeline Product Profiles 324
AstraZeneca Plc - Company Statement 344
AstraZeneca Plc - Locations And Subsidiaries 348
Head Office 348
Other Locations & Subsidiaries 348
AstraZeneca Plc - Key Manufacturing Facilities 353
Appendix 354
Methodology 354
Coverage 354
Secondary Research 354
Primary Research 354
Expert Panel Validation 354
Contact Us 354
Disclaimer 355
List of Tables
AstraZeneca Plc, Key Information 22
AstraZeneca Plc, Key Facts 22
AstraZeneca Plc - Pipeline by Indication, 2016 24
AstraZeneca Plc - Pipeline by Stage of Development, 2016 33
AstraZeneca Plc - Monotherapy Products in Pipeline, 2016 34
AstraZeneca Plc - Combination Treatment Modalities in Pipeline, 2016 35
AstraZeneca Plc - Partnered Products in Pipeline, 2016 36
AstraZeneca Plc - Partnered Products/ Combination Treatment Modalities, 2016 37
AstraZeneca Plc - Out-Licensed Products in Pipeline, 2016 39
AstraZeneca Plc - Out-Licensed Products/ Combination Treatment Modalities, 2016 40
AstraZeneca Plc - Pre-Registration, 2016 41
AstraZeneca Plc - Filing rejected/Withdrawn, 2016 42
AstraZeneca Plc - Phase III, 2016 43
AstraZeneca Plc - Phase II, 2016 44
AstraZeneca Plc - Phase I, 2016 46
AstraZeneca Plc - Preclinical, 2016 48
AstraZeneca Plc - Discovery, 2016 51
AstraZeneca Plc - Pipeline by Target, 2016 251
AstraZeneca Plc - Pipeline by Route of Administration, 2016 260
AstraZeneca Plc - Pipeline by Molecule Type, 2016 261
AstraZeneca Plc - Pipeline Products by Mechanism of Action, 2016 262
AstraZeneca Plc - Recent Pipeline Updates, 2016 268
AstraZeneca Plc - Dormant Developmental Projects,2016 330
AstraZeneca Plc - Discontinued Pipeline Products, 2016 333
AstraZeneca Plc, Subsidiaries 362
AstraZeneca Plc, Key Manufacturing Facilities 367
List of Figures
AstraZeneca Plc - Pipeline by Top 10 Indication, 2016 24
AstraZeneca Plc - Pipeline by Stage of Development, 2016 33
AstraZeneca Plc - Monotherapy Products in Pipeline, 2016 34
AstraZeneca Plc - Combination Treatment Modalities in Pipeline, 2016 35
AstraZeneca Plc - Partnered Products in Pipeline, 2016 36
AstraZeneca Plc - Out-Licensed Products in Pipeline, 2016 39
AstraZeneca Plc - Pipeline by Top 10 Target, 2016 251
AstraZeneca Plc - Pipeline by Route of Administration, 2016 260
AstraZeneca Plc - Pipeline by Molecule Type, 2016 261
AstraZeneca Plc - Pipeline Products by Top 10 Mechanism of Action, 2016 262
